Upstream Bio, Inc.
UPB
$8.56
-$0.09-1.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -11.56% | 36.22% | -2.25% | -2.22% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -11.56% | 36.22% | -2.25% | -2.22% | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -11.56% | 36.22% | -2.25% | -2.22% | |
| SG&A Expenses | 71.18% | 59.89% | 83.28% | 50.93% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 108.13% | 82.21% | 94.86% | 76.80% | |
| Operating Income | -113.24% | -83.66% | -101.29% | -83.11% | |
| Income Before Tax | -150.32% | -79.51% | -415.54% | -288.93% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -150.32% | -79.51% | -415.54% | -288.93% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -150.32% | -79.51% | -415.54% | -288.93% | |
| EBIT | -113.24% | -83.66% | -101.29% | -83.11% | |
| EBITDA | -113.13% | -83.49% | -101.50% | -83.27% | |
| EPS Basic | 89.13% | 90.52% | -229.20% | -53.93% | |
| Normalized Basic EPS | 86.01% | 88.29% | -404.52% | -263.61% | |
| EPS Diluted | 89.13% | 90.52% | -229.20% | -53.93% | |
| Normalized Diluted EPS | 86.01% | 88.29% | -404.52% | -263.61% | |
| Average Basic Shares Outstanding | 1,689.88% | 1,433.30% | 2.18% | 6.96% | |
| Average Diluted Shares Outstanding | 1,689.88% | 1,433.30% | 2.18% | 6.96% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |